# US 4,400,384 A · 5-o-Cyanobenzyl-4,5,6,7-tetrahydrothieno [3,2-c] pyridine methanesulfonate and other novel salts thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 4,400,384 A
- Document ID: US4400384A
- Status: Granted
- Kind: A
- Application number: 06/193,906
- Filed: 1980-10-06
- Granted: 1983-08-23
- Earliest claimed: 1980-10-06
- Assignees: Sanofi
- Inventors: Armand Amselem; Fernand Eloy; Jean-Pierre Maffrand
- Web page: https://patentgrep.com/patent/US4400384A

## CPC

- C07D 495/04: Ortho-condensed systems
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)

## Abstract

The invention concerns novel 5-o-cyanobenzyl-4, 5, 6, 7-tetrahydrothieno-[3,2-c] pyridine acid addition salts having inhibitory action against blood platelet aggregation without anti-inflammatory activity, and the compositions and methods of use therefor.

## Claims

### Claim 1

The methanesulfonate acid addition salt of 5-o-cyanobenzyl-4,5,6,7-tetrahydrothieno [3,2-c] pyridine.

### Claim 2

An acid addition salt of 5-o-cyanobenzyl-4,5,6,7-tetrahydrothieno [3,2-c] pyridine selected from the group consisting of the hydrochloride, nitrate, hemifumarate and hemitartrate salts.

### Claim 3 (depends on 2)

The hydrochloride salt of claim 2.

### Claim 4 (depends on 2)

The nitrate salt of claim 2.

### Claim 5 (depends on 2)

The hemifumarate salt of claim 2.

### Claim 6 (depends on 2)

The hemitartrate salt of claim 2.

### Claim 7

A therapeutic composition having blood-platelet aggregation activity without anti-inflammatory or vasodilator activity, which comprises the methanesulfonate acid addition salt of 5-o-cyanobenzyl-4,5,6,7-tetrahydrothienopyridine in an amount effective to inhibit blood-platelet aggregation, and a pharmaceutically acceptable carrier.

### Claim 8

A therapeutic composition having blood-platelet aggregation activity without anti-inflammatory or vasodilator activity, which comprises an acid addition salt of 5-o-cyanobenzyl-4,5,6,7-tetrahydrothieno [3,2-c] pyridine selected from the group consisting of the hydrochloride, nitrate, hemifumarate and hemitartrate salts in an amount effective to inhibit blood-platelet aggregation, and a pharmaceutically acceptable carrier.

### Claim 9 (depends on 8)

The therapeutic composition of claim 8 comprising the hydrochloride salt.

### Claim 10 (depends on 8)

The therapeutic composition of claim 8 comprising the nitrate salt.

### Claim 11 (depends on 8)

The therapeutic composition of claim 8 comprising the hemifumarate salt.

### Claim 12 (depends on 8)

The therapeutic composition of claim 8 comprising the hemitartrate salt.

### Claim 13 (depends on 7)

A therapeutic dosage unit comprising the composition of claim 7 and containing from about 0.025 g to about 0.5 g of said methanesulfonate salt.

### Claim 14 (depends on 8)

A therapeutic dosage unit comprising the composition of claim 8 and containing from about 0.025 g to about 0.5 g of said hydrochloride salt.

### Claim 15 (depends on 8)

A therapeutic dosage unit comprising the composition of claim 8 and containing from about 0.025 g to about 0.5 g of said nitrate salt.

### Claim 16 (depends on 8)

A therapeutic dosage unit comprising the composition of claim 8 and containing from about 0.025 g to about 0.5 g of said hemifumarate salt.

### Claim 17 (depends on 8)

A therapeutic dosage unit comprising the composition of claim 8 and containing from about 0.025 g to about 0.5 g of said hemitartrate salt.

### Claim 18 (depends on 7)

A method for the treatment of the warm-blooded animal to inhibit blood-platelet aggregation which comprises administering the composition of claim 7 to said animal in an amount effective to inhibit blood-platelet aggregation and causing said inhibition without causing anti-inflammatory or vasodilator activity in said animal.

### Claim 19 (depends on 8)

A method for the treatment of a warm-blooded animal to inhibit blood-platelet aggregation which comprises administering the composition of claim 8 to said animal in an amount effective to inhibit blood-platelet aggregation and causing said inhibition without causing anti-inflammatory or vasodilator activity in said animal.

### Claim 20 (depends on 19)

The method of claim 19 wherein the active ingredient is said hydrochloride salt.

### Claim 21 (depends on 19)

The method of claim 19 wherein the active ingredient is said nitrate salt.

### Claim 22 (depends on 19)

The method of claim 19 wherein the active ingredient is said hemifumarate salt.

### Claim 23 (depends on 19)

The method of claim 19 wherein the active ingredient is said hemitartrate salt.

### Claim 24 (depends on 18)

The method of claim 18 wherein the composition is administered in a dosage of abut 0.025 g to about 1 g of active ingredient per 24 hours.

### Claim 25 (depends on 19)

The method of claim 19 wherein the composition is administered in a dosage of abut 0.025 g to about 1 g of active ingredient per 24 hours.

### Claim 26 (depends on 7)

A method for the treatment of a warm-blooded animal to inhibit thrombic, sludge or spasmodic activity, which comprises administering the composition of claim 7 to said animal in an amount effective to inhibit at least one of said activities without inducing analgesic, hemostasis or central nervous system activity in said animal.